Call Us Today! 1-855-835-7172|

Intact Genomics Receives ISO 13485 Certification

St. Louis, MO. (August 7, 2023) – Intact Genomics (IG®), a leading provider of cutting-edge molecular biology products and services, is proud to announce that it has been granted the prestigious ISO 13485:2016 certification for the design, development, manufacture and distribution of molecular biology products and services, in standard or custom format for both industries and academic institutes.

ISO 13485 is an internationally recognized standard specifically tailored for medical device manufacturers and companies involved in the design, development, production, and distribution of in vitro diagnostic (IVD) kits and reagents. The certification process involves a rigorous evaluation of a company’s quality management system, ensuring that it complies with the stringent requirements set forth by the ISO 13845 standards.

“Receiving the ISO 13485 certification is a significant milestone for Intact Genomics, ” said Dr. Chengcang Charles Wu, CEO of Intact Genomics. ” This milestone reflects the hard work and collective effort of our entire team to uphold the highest quality standards in our industry. With ISO 13485 certification, our customers can have even greater confidence in the reliability and performance of our molecular biology solutions.”

“Our team has worked tirelessly to implement and adhere to the standards set by ISO 13485,” said Dr. David Brent Halling, Leader of Protein Products Development and Laboratories Manager. “Intact Genomics’ certification to this standard proves and demonstrates to the international community that our products are made with strict adherence to traceability and quality control. This achievement reflects our unwavering commitment to delivering reliable and precise products and services for molecular biology research and diagnostics applications. It also showcases our dedication to meeting the needs and expectations of our valued customers and collaborators.”

The ISO 13485 certification further solidifies Intact Genomics’ position as a trusted partner in the molecular biology industry. The company remains committed to ongoing quality improvement initiatives, ensuring that its products and services continue to meet the evolving needs of the scientific community.

About Intact Genomics, Inc.

Established in 2013, Intact Genomics is a worldwide leader in large DNA fragment cloning and metagenomics technologies. The company continuously focuses on genomic technology innovation by applying large DNA fragment cloning related proprietary technologies in metagenomic research to develop new solutions for natural product-enzyme discovery, agricultural research, and environmental protection. Intact Genomics also provides high-quality life science products and services to help scientists explore the genome structure and function of microorganisms, plants, and animal species. We are proud to provide products and services for more than 2,000 laboratories worldwide.

Intact Genomics® and IG® are registered trademarks of Intact Genomics, Inc.

Media Contact:

Andrew Robertson
Vice President of Sales & Marketing
Intact Genomics
11840 Westline Industrial Drive, Suite 120
St. Louis, MO 63146
Phone: 314-942-3655 ext. 102

Wazoku Crowd Challenge awarded Intact Genomics a first place in the USA

Intact Genomics won first place in the USA from Wazoku Crowd Challenge 12091216978 for our scientist’s submission to Corteva Agriscience™ Open Innovation opportunity on Novel solutions for fungal nucleic acid extraction in May 2023. Intact Genomics is the worldwide leader in large DNA fragment extraction, cloning & metagenomic technologies. Our patented Fungal Artificial Chromosome (FAC) technology can capture large DNA fragments up to 300 kb and shuttle them into advanced or engineered fungal hosts for heterologous expression.

Intact Genomics changed the company logo

Intact Genomics changed its DNA arch logo to an exciting new “IG with DNA” design in April 2023. Our previous logo was designed by our founders when they started the company in St. Louis, Missouri. They were inspired by the adventure spirit of Gateway Arch and beauty of DNA. However, as we continue to grow, we believe that our new logo captures the essence of our vision for the future. IG®  and Intact Genomics®  are registered trademarks granted by the United States Patent and Trademark Office (USPTO) to Intact Genomics, Inc. The new logo features a modern, vibrant and dynamic design that reflects our commitment to innovation and staying current in the ever-changing business landscape. It embodies our company’s values of creativity, connectivity, and integrity, which align with the DNA of Intact Genomics.

Intact Genomics Exhibited and Presented at Plant & Animal Genome Conference (PAG) 30, January 13th-18th, 2023

At Plant & Animal Genome Conference (PAG) 30, hundreds of attendees visitted us at Booth 124, and talked with our VP of sales, Mr. Andy Robertson, and/or CEO, Dr. Chengcang Charles Wu to learn more about our new products, services and technologies. Intact Genomics provides superior molecular biology research products including agrobacterium competent cells, Quick10cloning kit, recombinase polymerase amplification (RPA) optimization enzymes, custom competent cells and custom genomic services to meet your research needs and serve the worldwide plant and animal genome R&D community.
Dr. Wu also presented “A novel DirectPlate®  chemical competent cell technology ” within the workshop, “Development and Application of Genome Engineering and Transgenic Technology to the Agriculture.”

Intact Genomics presented at 4th International Conference on Natural Product Discovery and Development in the Genomic Era on Jan. 8-12, 2023

Intact Genomics had two poster presentations of our recent progresses on drug discovery R&D:
Chengcang Charles WU1, Andrea Stierle2, Donald Stierle2, Hongyu Chen1, Peter Korajczyk1, Rosa Ye1, Jeremie Ferey1 and Niel Mondava2, (1)INTACT GENOMICS, INC, ST LOUIS, MO, USA, (2)University of Montana, Missoula, MT, USA

Dr. Sung Chul Park1, Dr. Jin Woo Bok1, Rosa Ye2, Raveena Gupta3, Matthew Robey4, Dr. Chengcang Charles Wu2, Prof. Neil Kelleher4 and Prof. Nancy P. Keller1, (1)University of Wisconsin-Madison, Madison, WI, USA, (2)INTACT GENOMICS, INC, ST LOUIS, MO, USA, (3)Northwestern University, USA, (4)Northwestern University, Evanston, IL, USA

Intact Genomics Awarded $2.94M SBIR Direct Phase II Grant from National Institute of Allergy and Infectious Diseases of NIH

On July 1, 2022, Intact Genomics announced that it has received a three-year Small Business Innovation Research (SBIR) Direct Phase II grant from the National Institute of Allergy and Infectious Diseases of the National Institute of Health. The total award is 2.94M. The company will develop new technology for rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes (FACs).

“High through-put genome sequencing technologies opened the door for the discovery of natural products from filamentous fungi for therapeutic, agricultural, and other applications,” said Dr. Chengcang Charles Wu, founder, and CEO of Intact Genomics. “During a span of 50 years, from the 1940s to the 1990s, microbial natural product discovery provided the most important sources for fungicides, insecticides, antibiotics, anti-cancer agents, immune-modulators, and anthelminthic agents.  However, since the 1990s, microbial natural product discovery has become became less productive due to rediscovery issues, low throughput, and lack of relevant new technologies to unveil less abundant or not easily detected drug-like natural products. New discovery technologies of fungal natural products including antiMRSA antibiotics are urgently needed to meet the rapidly rising demand for anti-infectious, anticancer, and other therapeutic agents in the future. Sponsored by NIAID, Intact Genomics will collaborate with Dr. Andrea Stierle laboratory of the University of Montana to develop antiMRSA antibiotic biosynthesis to solve these problems.”

Intact Genomics Expanded and Moved to a New Location at 11840 Westline Industrial Drive in June, 2022

On June 28, 2022, Intact Genomics successfully graduated from Helix Center Biotech Incubator in St. Louis, Missouri, USA and moved to a nearby brand-new remodeled facility at 11840 Westline Industrial Drive.

Our new facility includes state-of-the-art laboratory areas and office area, meeting room and breakroom under one roof, allowing for seamless collaboration across functional teams. This new space provides our growing team with a quiet, safe, beautiful and inspiring workspace to develop cutting-edge technologies and provide better life science products and services for our customers around the world.

Intact Genomics Sponsored The 32nd International Conference on Arabidopsis Research (ICAR2022) in Ireland

Intact Genomics Sponsored The 32nd International Conference on Arabidopsis Research (ICAR2022) on June 20-24 in Ireland. The International Conference on Arabidopsis Research (ICAR) is an annual gathering of up to thousand scientists whose primary research organism is the model plant Arabidopsis thaliana. This meeting embraces the remarkable contribution that Arabidopsis has made to our understanding of plant science.

Plant science can make big impacts on sustainable agriculture, forestry, environmental conservation, biodiversity protection and climate action, as well as in the production of nutritious food and plant-based non-food products – such as paper, timber, chemicals, energy and pharmaceuticals. Plant scientists contribute to a diverse range of key industries including agriculture, pharmaceuticals, forestry, food and biotechnology.


Go to Top